Hard-knock Life – still seeking buyer
This article was originally published in Clinica
Executive Summary
Genome sequencing firm Life Technologies still hasn't found a buyer and might need to lower its expectations, in order to tempt the likes of Roche and Thermo Fisher Scientific. That is the view of Doug Schenkel, analyst at Cowen Group, who has just downgraded Life to "neutral" from his previous rating of "outperform".